Stratrix
On the Record · Abbott Laboratories

Abbott Laboratories acquisitions, on the record

The businesses Abbott Laboratories bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

BusinessDealWhenValue
Bigfoot Biomedical, Inc. (Bigfoot)
Word for word“On September 22, 2023, Abbott completed the acquisition of Bigfoot Biomedical, Inc. (Bigfoot), which will further Abbott's efforts to develop connected solutions for making diabetes management more personal and precise.” 10-K for 2023
acquisitionSeptember 22, 2023—
Cardiovascular Systems, Inc. (CSI)
Word for word“On April 27, 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc. (CSI) for $ 20 per common share, which equated to a purchase price of $ 851 million.” 10-K for 2023
acquisitionApril 27, 2023—
Walk Vascular, LLC (Walk Vascular)
Word for word“In September 2021, Abbott acquired Walk Vascular, LLC (Walk Vascular), a commercial-stage medical device company with a minimally invasive thrombectomy system designed to remove peripheral blood clots.” 10-K for 2023
acquisitionSeptember 2021—
Exact Sciences Corporation
Word for word“On November 19, 2025, Abbott entered into a definitive agreement to acquire Exact Sciences Corporation (Exact Sciences), which is expected to enable Abbott to enter the cancer diagnostics market.” 10-K for 2025
agreed acquisitionNovember 19, 2025—
Bigfoot Biomedical, Inc.
Word for word“On September 22, 2023, Abbott completed the acquisition of Bigfoot Biomedical, Inc. (Bigfoot), which furthers Abbott's efforts to develop connected solutions for making diabetes management more personal and precise.” 10-K for 2025
acquisitionSeptember 22, 2023—
Cardiovascular Systems, Inc.
Word for word“On April 27, 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc. (CSI) for $ 20 per common share, which equated to a purchase price of $ 851 million .” 10-K for 2025
acquisitionApril 27, 2023$ 851 million
As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year endedCash paid for acquisitions (net of cash acquired)Goodwill from acquisitions
2016-12-31$80 million$79 million
2017-12-31$17.18 billion—

Deal filings since 2016

Read from Abbott Laboratories’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-20. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.